Introduction
Depression is a frequent comorbidity in multiple sclerosis (MS) and considerably reduces patients’ quality of life, regardless of disability status. Clinically significant depressive symptoms occur in 19%–40% of MS patients, double the reported prevalence in the general population.

The etiology of depression in MS is likely multifactorial and may include both psychological and biological components. The stress reaction of receiving an MS diagnosis may contribute to the elevated risk of depression diagnosis and antidepressant use. Other evidence suggests an association between depression and risk of subsequent MS diagnosis, not attributable to genetic liability. Some elements of neuroinflammation may also represent biological denominators for both conditions.

Whether disease-modifying therapies (DMTs) modify the risk of depression in relapsing-remitting MS (RRMS) is unclear, and comparisons across newer DMTs are rare. The main objective of this study was to determine whether DMT choice modulated the subsequent risk of being diagnosed with depression or using antidepressants in a large nationwide cohort of RRMS patients with no history of depression or antidepressant use before first DMT. The secondary aim was to examine whether occurrence of depression or use of antidepressants

Date received: 26 February 2021; revised: 18 June 2021; accepted: 22 June 2021
affected the risk of DMT discontinuation or experiencing an MS relapse.

Method
We performed a nationwide cohort study of RRMS patients, free of diagnosed depression and antidepressant use prior to first DMT, linking the Swedish MS Registry to national healthcare and census registers.

Study design
The Swedish MS Registry is a web-based resource collecting high-quality healthcare data for all MS patients in Sweden since 2001. It is an integrated part of Swedish MS care; patients are informed orally about the data collection process and are free to opt out. Despite participation in the registry being voluntary, both for the patients and their attending neurologists, the registry includes about 80% of MS patients in Sweden with approximately 18,000 patients in total. Consistent with national guidelines recommending treatment for MS patients with active disease, only about 5% of patients have no recorded DMT in the MS Registry (including patients with missing therapy data). Overall, data collected in this registry have been shown as both accurate and complete. We defined our study population as all patients included in the Swedish MS Registry residing in Sweden from 5 years prior to MS diagnosis or longer and first diagnosed with RRMS from January 2010 to September 2018 \( (N = 4771) \). Through the unique personal identification numbers assigned to all Swedish residents, we cross-linked our study population to the Swedish Migration Register and the Swedish Causes of Death Register to national healthcare and census registers.

Ascertainment of depression diagnosis and antidepressant use
We further cross-linked our study population to the Swedish Patient Register and the Swedish Prescribed Drug Register to extract information about depression diagnosis and antidepressant use. The Swedish Patient Register collects information about inpatient care since 1964, and hospital-based outpatient specialist care since 2001. Each diagnosis in the Patient Register is classified according to the Swedish Revisions of the International Classification of Diseases (ICD) codes (ICD-10 from 1997). The Prescribed Drug Register includes information on all dispensed prescribed drugs in Sweden since July 2005, classified according to the Anatomical Therapeutics Chemical (ATC) system. We identified clinical diagnosis of depression at inpatient or outpatient visits, using ICD-10 codes F32-34 or F38-39 \( (N = 519, 10.9\% ) \). We defined patients as antidepressant users if they had filled at least two antidepressant prescriptions, with the date of first prescription fill used as the start date. We identified antidepressant prescription fills, including selective serotonin reuptake inhibitors (SSRIs), non-selective monoamine oxidase (MAO) inhibitors, MAO A inhibitors, and other antidepressants (including serotonin and norepinephrine reuptake inhibitors, but not duloxetine) using ATC codes N06AB, N06AF, N06AG, and N06AX except N06AX21 \( (N = 1370, 28.7\% ) \). Non-selective monoamine reuptake inhibitors including tricyclic antidepressants (ATC code N06AA) and duloxetine (ATC code N06AX21) were excluded because they may be used to treat neuropathic pain in MS patients \( (N = 582, 12.2\% ) \). We excluded RRMS patients who did not have any recorded DMT \( (N = 245, 5.1\% ) \) and patients who were diagnosed with depression or had filled an antidepressant prescription during the 5 years prior to the start of first DMT \( (N = 723, 5.72\%) \), leaving 3803 patients in the analyses \( (79.7\% ) \).

Depression and antidepressant use in relation to different DMTs
Because patients could have different DMTs during the follow-up, we considered DMTs as time-varying variables and compared all time periods when patients were treated with dimethyl fumarate, fingolimod, glatiramer acetate, natalizumab, or rituximab, with time periods when patients were treated with interferons (interferon beta-1a and interferon beta-1b). Other DMTs were used less frequently, and collapsed to one group including alemtuzumab, daclizumab, hematopoietic stem cell transplantation, mitoxantrone, and teriflunomide. We followed all patients from start of each DMT to date of depression diagnosis or antidepressant prescription filling, DMT discontinuation, migration out of Sweden, withdrawal from the Swedish MS Registry, or end of follow-up (31 December 2018), whichever came first.

DMT discontinuation or MS relapse in relation to depression or antidepressant use
We regarded depression diagnosis and antidepressant use as time-varying exposures and considered patients exposed from the date of first depression diagnosis or first prescription fill of antidepressants. We followed all patients from start of DMT to date of DMT
discontinuation or relapse, migration out of Sweden, withdrawal from the MS Registry, or end of follow-up. Since DMT discontinuation was interpreted as a poor treatment outcome, the following were considered censoring events and not counted as outcome events: discontinuation with the stated reason being a stable condition, planned pregnancy, or pregnancy.

**Potential confounding factors**

Potential confounders included demographic factors, psychiatric comorbidity, and MS severity. Demographic factors included sex, country of birth, education, age at DMT start, and geographical region of treatment. We extracted information about education from the Swedish Longitudinal Integrated Database for Health Insurance and Labor Market Studies and selected for each observation the highest achieved education level at DMT start. We defined history of (1) bipolar disorder, (2) anxiety disorders, and (3) all other mental and behavioral disorders by the diagnoses of these disorders in the Swedish Patient Register during the 5 years before first DMT start (bipolar disorder ICD-10 codes: F30-F31, anxiety disorders: F40-48, all other mental and behavioral disorders: F00-F99 except F30-34, F40-48, or F38-39). We assessed MS severity through disease duration, that is, time since MS diagnosis at DMT start, DMT line, that is, number of previous DMTs, the Expanded Disability Status Scale (EDSS), and physical and psychological components of the MS Impact Scale (MSIS-29), recorded in the Swedish MS Registry. For each observation we selected the closest measurement recorded prior to DMT start. In the analysis of DMT discontinuation or relapse in relation to depression or antidepressant use we selected the closest measurement recorded prior to depression diagnosis or antidepressant prescription fill, if the patient was exposed to depression or antidepressant use.

**Statistical analyses**

We derived hazard ratios (HRs) and the corresponding 95% confidence intervals (CIs) from multivariable Cox proportional hazards regression models, to assess the risk of depression or antidepressant use in relation to different DMTs and to assess the risk of DMT discontinuation or MS relapse after DMT initiation in relation to depression or antidepressant use. We analyzed all types of DMTs collectively and stratified the analyses by specific DMT, focusing on interferons, dimethyl fumarate, fingolimod, glatiramer acetate, natalizumab, and rituximab.

In all analyses we used time since DMT start as the underlying timescale. In the first model, we adjusted for sex, country of birth, education, age at DMT start, and, to account for an uneven distribution of DMT treatment across the country, geographical region of treatment. In the second model, to account for the collective effect of psychiatric comorbidity, we further adjusted all associations for history of bipolar disorder, anxiety disorders, and all other mental and behavioral disorders at first DMT start. Finally, to account for the impact of MS severity on the studied associations, in the third model we additionally adjusted for disease duration, DMT line, EDSS, and MSIS-29.

We addressed missing data in the Swedish MS Registry using multiple imputation with the fully conditional specification method and 25 imputations with 30 burn-in iterations. We made separate imputations for each outcome and included in the imputation models all covariates, the specific event, and the Nelson–Aalen estimator of the cumulative hazard substituting the time to event.

As patients change DMTs during the course of the disease, we used a sandwich estimator to account for the fact that patients could belong to multiple treatment cohorts. We considered associations with a two-sided p value $$\leq 0.05$$ statistically significant.

**Sensitivity analyses**

We repeated all analyses after further excluding patients with a history of depression longer than 5 years prior to first DMT start ($N = 184$).

Because SSRIs are considered as a first line treatment of depression in current guidelines, we also repeated all analyses after restricting our definition of antidepressants to SSRIs only (ATC code N06AB).

We performed all analyses using Stata software, version 16.1 (StataCorp, College Station, TX). The Regional Ethical Review Board in Stockholm, Sweden, approved this study. Data are available upon approval from the respective register holders.

**Results**

Baseline characteristics at the start of first DMT of the 3803 patients included in the analyses are presented in Table 1. The median age at diagnosis of RRMS was 35.3 years (interquartile range (IQR) = 16.3).

Missing data were <1% for all variables except EDSS (36%–38% of all DMT episodes), and physical and psychological component of MSIS-29 (45%–48% of all DMT episodes).
During follow-up, 43.9% of the patients were ever treated with interferons (N = 1667) for a total exposure time of 3779.5 years, whereas 28.3% were ever treated with dimethyl fumarate (N = 1077, total exposure time = 1884.2 years), 13.1% with fingolimod (N = 497, total exposure time = 1102.7 years), 10.8% with glatiramer acetate (N = 411, total exposure time = 848.0 years), 23.0% with natalizumab (N = 874, total exposure time = 2015.4 years), 43.2% with rituximab (N = 1644, total exposure time = 3195.6 years), and 9.1% with other DMTs (N = 347, total exposure time = 594.3 years).

Table 1. Baseline characteristics at the start of first DMT of patients diagnosed with RRMS in the Swedish MS Registry, January 2010 to September 2018, without a history of depression diagnosis or antidepressant prescription fill in the prior 5 years.

| First DMT, N (%) | Interferons | Dimethyl fumarate | Fingolimod | Glatiramer acetate | Natalizumab | Rituximab | All a |
|-----------------|-------------|------------------|------------|-------------------|-------------|-----------|-------|
| N = 1618        | 1113 (68.8) | 397 (68.6)       | 84 (64.1)  | 162 (75.7)        | 295 (66.7)  | 450 (64.4) | 2575 (67.7) |
| Country of birth |             |                  |            |                   |             |           |       |
| Sweden          | 1444 (89.2) | 508 (87.7)       | 110 (84.0) | 198 (92.5)        | 394 (89.1)  | 621 (88.8) | 3383 (89.0) |
| Other           | 174 (10.8)  | 70 (12.1)        | 21 (16.0)  | 16 (7.5)          | 48 (10.9)   | 77 (11.0)  | 418 (11.0)  |
| Education       |             |                  |            |                   |             |           |       |
| Primary or lower secondary | 151 (9.3) | 58 (10.0)       | 15 (11.5)  | 22 (10.3)         | 60 (13.6)   | 70 (10.0)  | 386 (10.2)  |
| Upper secondary  | 702 (43.4)  | 245 (42.3)      | 59 (45.0)  | 102 (47.7)        | 202 (45.7)  | 302 (43.2) | 1668 (43.9) |
| Postsecondary or postgraduate | 754 (46.6) | 267 (46.1)      | 54 (41.2)  | 88 (41.1)         | 170 (38.5)  | 316 (45.2) | 1703 (44.8) |
| Age at DMT start (years) |             |                  |            |                   |             |           |       |
| 9–20            | 82 (5.1)    | 30 (5.2)        | 14 (10.7)  | 12 (5.6)          | 51 (11.5)   | 39 (5.6)   | 232 (6.1)   |
| 21–40           | 949 (58.6)  | 376 (64.9)      | 83 (63.4)  | 131 (61.2)        | 323 (73.1)  | 393 (56.2) | 2312 (60.8) |
| 41–60           | 557 (34.4)  | 160 (27.6)      | 33 (25.2)  | 67 (31.3)         | 67 (15.2)   | 250 (35.8) | 1189 (31.3) |
| 61–78           | 30 (1.9)    | 13 (2.3)        | 1 (0.8)    | 4 (1.9)           | 1 (0.2)     | 17 (2.4)   | 70 (1.8)    |
| Geographical region of treatment |             |                  |            |                   |             |           |       |
| North Sweden    | 166 (10.3)  | 57 (9.8)        | 12 (9.2)   | 47 (22.0)         | 57 (12.9)   | 176 (25.2) | 533 (14.0)  |
| Stockholm       | 349 (21.6)  | 131 (22.6)      | 25 (19.1)  | 34 (15.9)         | 73 (16.5)   | 242 (34.6) | 879 (23.1)  |
| Southeast Sweden| 240 (14.8)  | 73 (12.6)       | 26 (19.9)  | 21 (9.8)          | 45 (10.2)   | 72 (10.3)  | 492 (12.9)  |
| South Sweden    | 318 (19.7)  | 100 (17.3)      | 33 (25.2)  | 57 (26.6)         | 91 (20.6)   | 56 (8.0)   | 673 (17.7)  |
| Uppsala-Örebro  | 243 (15.0)  | 77 (13.3)       | 10 (7.6)   | 29 (13.6)         | 59 (13.4)   | 94 (13.5)  | 529 (13.9)  |
| West Sweden     | 302 (18.7)  | 141 (24.4)      | 25 (19.1)  | 26 (12.2)         | 117 (26.5)  | 59 (8.4)   | 697 (18.3)  |
| History of clinical diagnoses of mental and behavioral disordersb |             |                  |            |                   |             |           |       |
| Bipolar disorder| 3 (0.2)     | 3 (0.5)         | 1 (0.8)    | 1 (0.5)           | 1 (0.2)     | 2 (0.3)    | 11 (0.3)    |
| Anxiety disorders| 37 (2.3)  | 20 (3.5)        | 1 (0.8)    | 8 (3.7)           | 16 (3.6)    | 25 (3.6)   | 109 (2.9)   |
| Other c         | 28 (1.7)    | 22 (3.8)        | 3 (2.3)    | 5 (2.3)           | 26 (5.9)    | 28 (4.0)   | 113 (3.0)   |
| MS severity scales, median (IQR)d |             |                  |            |                   |             |           |       |
| EDSS            | 1.0 (2.0)   | 1.0 (2.0)       | 1.5 (2.5)  | 1.0 (2.0)         | 2.0 (2.0)   | 2.0 (1.5)  | 1.5 (2.5)   |
| MSIS-29 physical| 1.3 (0.8)   | 1.4 (0.8)       | 1.4 (0.9)  | 1.5 (1.1)         | 1.8 (1.5)   | 1.5 (1.1)  | 1.4 (0.9)   |
| MSIS-29 psychological | 2 (1.2) | 2.0 (1.3)       | 2.2 (1.3)  | 2.6 (1.3)         | 2.3 (1.4)   | 2.2 (1.4)  | 2.1 (1.5)   |

DMT: disease-modifying therapies; EDSS: Expanded Disability Status Scale, IQR: interquartile range; MS: multiple sclerosis; MSIS-29: MS Impact Scale; N = number of individuals; RRMS: relapsing-remitting MS.
aIncluding other DMTs (alemtuzumab, daclizumab, hematopoietic stem cell transplantation, mitoxantrone, and teriflunomide).
bDiagnosed within 5 years prior to DMT start.
cAll mental and behavioral disorders except depression, bipolar disorder, and anxiety disorders.
dAfter imputing missing data.

Depression and antidepressant use in relation to different DMTs

Eleven point five per cent patients received a first diagnosis of depression or used antidepressants after a median time of 1.59 years from DMT start (IQR = 2.30). The risk of depression or antidepressant use was lower
during treatment with rituximab, compared with treatment with interferons (Table 2). Stratifying the analysis on sex showed no clear evidence of effect modification (Supplementary Tables 1–2).

**DMT discontinuation or MS relapse in relation to depression or antidepressant use**

The median time from DMT start to DMT discontinuation was 1.81 years (IQR = 2.39). DMT discontinuation was followed by DMT switch for most patients, with 3480 patients (91.5%) still on treatment by the end of follow-up, 291 patients with no recorded DMT after their last DMT interruption (7.6%), and 32 censored (0.8%). The median time from DMT start to MS relapse was 1.73 years (IQR = 2.45). The overall risk of DMT discontinuation after DMT initiation did not differ by depression diagnosis or antidepressant use (Table 3), nor did the overall risk of an MS relapse (Table 4).

After stratifying the analyses of treatment discontinuation by DMTs (Table 3), we found a higher risk of interferon discontinuation among patients with depression when compared to patients without depression and a higher risk of fingolimod discontinuation among patients who used antidepressants compared to patients who did not use antidepressants.

**Sensitivity analyses**

Further excluding patients with a history of depression longer than 5 years prior DMT start rendered similar results to the main analyses although with wider CIs (Supplementary Tables 3–5), as did restricting the definition of antidepressants to SSRIs only (Table 5).

**Discussion**

Using a nationwide population-based cohort of RRMS patients, we found that patients treated with rituximab had a lower risk of receiving a depression diagnosis or using antidepressants as compared with patients treated with interferons. We also found that patients with a depression diagnosis had an increased risk of discontinuing interferons compared with patients without depression, while patients who used antidepressants had an increased risk of discontinuing fingolimod treatment compared with patients who did not use antidepressants. Being diagnosed with depression or using antidepressants did not influence the overall risk of DMT discontinuation or MS relapse.

Fingolimod and natalizumab have been reported to improve depressive symptoms in MS patients with pre-existing depressive symptoms. On the contrary, other DMTs have been associated with worsening of depressive symptoms, in particular among patients on interferon beta-1b treatment with a past history of depression. Early trials also indicated a higher frequency of depressive symptoms, relative to placebo, in patients treated with interferon beta-1b. These associations, though, seemed to be explained by history of psychiatric disorders prior to initiation of interferon beta-1b and were not replicated by larger subsequent studies. Still, depression is listed as a possible side effect not only for interferon beta-1b, but all currently approved DMTs.
Although rituximab is not an approved treatment for RRMS it has become the most widely used DMT in Sweden based on a series of studies in real world cohorts demonstrating superior clinical outcomes than regular MS DMTs.

Natalizumab, and to some degree also dimethyl fumarate and fingolimod, are also considered among highly effective MS DMTs. The absence of a consistently lower risk of depression with these treatments could indicate a role for B cells in relation to depressive symptoms. However, a causal relationship between B-cell depleting therapies and the risk of depression remains to be shown. It is also important to consider the mode of administration of the studied DMTs when interpreting the results. Rituximab is dosed twice a year. Natalizumab requires monthly visits at an infusion clinic. Dimethyl fumarate and fingolimod are taken orally daily, whereas interferons and glatiramer acetate are given as regular self-administered injections. It is possible that these differences influence the risk of being diagnosed with depression due to varying level of contact with healthcare providers. Further studies are therefore needed to address whether there is a true protective

Table 3. Associations of depression or antidepressant use with the risk of DMT discontinuation among RRMS patients (N = 3803), stratified analyses by DMTs.

|                  | Model 1a           | Model 2a           | Model 3a           |
|------------------|--------------------|--------------------|--------------------|
|                  | HR (95% CI)        | HR (95% CI)        | HR (95% CI)        |
| All DMTs         |                    |                    |                    |
| Depression diagnosis | 1.01 (0.85–1.20)  | 1.01 (0.85–1.20)  | 1.03 (0.85–1.25)  |
| Antidepressant prescription | 1.04 (0.94–1.15)  | 1.04 (0.95–1.15)  | 1.06 (0.94–1.19)  |
| Interferons      |                    |                    |                    |
| Depression diagnosis | 1.59 (1.21–2.09)* | 1.58 (1.21–2.08)* | 1.51 (1.15–1.98)** |
| Antidepressant prescription | 1.29 (1.09–1.54)** | 1.29 (1.09–1.53)** | 1.14 (0.94–1.37)  |
| Dimethyl fumarate |                    |                    |                    |
| Depression diagnosis | 0.87 (0.54–1.39)  | 0.85 (0.53–1.37)  | 0.75 (0.46–1.21)  |
| Antidepressant prescription | 1.08 (0.82–1.43)  | 1.09 (0.82–1.44)  | 0.85 (0.63–1.16)  |
| Fingolimod       |                    |                    |                    |
| Depression diagnosis | 1.41 (0.83–2.39)  | 1.41 (0.82–2.42)  | 1.34 (0.76–2.37)  |
| Antidepressant prescription | 1.51 (1.11–2.07)*** | 1.54 (1.12–2.12)**** | 1.47 (1.04–2.08)** **** |
| Glatiramer acetate |                    |                    |                    |
| Depression diagnosis | 0.70 (0.33–1.47)  | 0.69 (0.32–1.47)  | 0.56 (0.26–1.20)  |
| Antidepressant prescription | 1.12 (0.80–1.56)  | 1.10 (0.79–1.53)  | 0.97 (0.68–1.37)  |
| Natalizumab      |                    |                    |                    |
| Depression diagnosis | 1.10 (0.68–1.80)  | 1.09 (0.66–1.79)  | 0.98 (0.60–1.65)  |
| Antidepressant prescription | 1.35 (1.02–1.77)***** | (1.01–1.75)****** | 1.19 (0.89–1.59)  |
| Rituximab        |                    |                    |                    |
| Depression diagnosis | 1.91 (0.82–4.46)  | 1.95 (0.85–4.45)  | 1.57 (0.63–3.91)  |
| Antidepressant prescription | 1.17 (0.63–2.15)  | 1.16 (0.62–2.16)  | 0.88 (0.45–1.74)  |

CI: confidence interval; DMTs: disease-modifying therapies; EDSS: Expanded Disability Status Scale; HR: hazard ratio; MS: multiple sclerosis; MSIS-29: MS Impact Scale; N: number of individuals; RRMS: relapsing-remitting MS.

aModel 1: adjusted for sex, country of birth, education, age at DMT start, and geographical region of treatment. Time since DMT start was used as the underlying timescale.

Model 2: further adjusted for history of bipolar disorder, anxiety, and other mental and behavioral disorders in addition to the variables adjusted for in Model 1.

Model 3: further adjusted for disease duration, DMT line, EDSS, and MSIS-29 in addition to the variables adjusted for in Model 2.

*p = 0.001; **p = 0.003; ***p = 0.009; ****p = 0.007; *****p = 0.030; ******p = 0.031; *******p = 0.038.
effect of rituximab on the risk of depression or whether the difference compared to interferons is due to a negative effect of the latter.

Additional studies using treatment satisfaction questionnaires and general quality of life scales may shed light on the relation between treatment tolerability and mode of administration and psychological wellbeing. It may be speculated that treatment of depression may bring additional benefits apart from just symptomatic relief by modulating MS-associated inflammatory responses and clinical outcomes. However, currently there is not sufficient data to support the general use of antidepressants among MS patients according to the American Academy of Neurology Guidelines\textsuperscript{30} and the consequences of untreated psychiatric comorbidity on the general wellbeing and quality of life of MS patients remains unknown.\textsuperscript{31}

In contrast to earlier studies reporting a negative effect of depression on DMT adherence\textsuperscript{32} and MS relapse,\textsuperscript{33} we did not find a significant effect of depression or antidepressant use on the overall risk of DMT discontinuation or experiencing an MS relapse. In the analysis of specific DMTs, we detected a higher risk of interferon discontinuation in patients diagnosed with depression. Our finding is in accord with the previously suggested association between a fatigue-depression interaction factor and interferon beta-1b discontinuation using an open label trial of 72 MS patients.\textsuperscript{34} We speculate that our result might partially be explained by the lack of effectiveness of interferon treatment, which was the main reason for interferon discontinuation among depressed patients. However, it remains to be shown whether the reported lack of effectiveness of interferon treatment was based on objective signs of ongoing inflammatory disease.

Table 4. Associations of depression or antidepressant use with the risk of MS relapse among RRMS patients ($N = 3803$), stratified analyses by DMTs.

|                         | Model 1$^a$ | Model 2$^a$ | Model 3$^a$ |
|-------------------------|------------|------------|------------|
|                         | HR (95% CI)| HR (95% CI)| HR (95% CI)|
| All DMTs                |            |            |            |
| Depression diagnosis    | 1.54 (0.89–2.66) | 1.57 (0.90–2.74) | 1.50 (0.85–2.65) |
| Antidepressant prescription | 1.19 (0.84–1.71) | 1.21 (0.84–1.73) | 1.21 (0.82–1.79) |
| Interferons             |            |            |            |
| Depression diagnosis    | 1.75 (0.67–4.52) | 1.87 (0.73–4.80) | 1.65 (0.63–4.35) |
| Antidepressant prescription | 1.29 (0.69–2.42) | 1.40 (0.75–2.61) | 1.25 (0.64–2.43) |
| Dimethyl fumarate       |            |            |            |
| Depression diagnosis    | 0.59 (0.07–4.53) | 0.69 (0.09–5.36) | 0.66 (0.08–5.11) |
| Antidepressant prescription | 1.01 (0.35–2.87) | 1.08 (0.38–3.09) | 1.15 (0.39–3.42) |
| Fingolimod              |            |            |            |
| Depression diagnosis    | 1.93 (0.41–8.91) | 1.10 (0.09–13.05) | 0.75 (0.06–9.51) |
| Antidepressant prescription | 1.61 (0.64–4.07) | 1.48 (0.59–3.73) | 0.90 (0.33–2.44) |
| Glatiramer acetate      |            |            |            |
| Depression diagnosis    | 1.22 (0.15–9.72) | 1.41 (0.18–11.00) | 1.45 (0.17–12.18) |
| Antidepressant prescription | 1.46 (0.48–4.44) | 1.70 (0.56–5.15) | 1.52 (0.47–4.99) |
| Natalizumab             |            |            |            |
| Depression diagnosis    | 3.61 (1.35–9.61)* | 3.13 (1.21–8.09)** | 2.60 (0.91–7.41) |
| Antidepressant prescription | 2.02 (0.89–4.61) | 2.01 (0.87–4.61) | 2.08 (0.84–5.17) |
| Rituximab               |            |            |            |
| Depression diagnosis    | 1.31 (0.31–5.56) | 1.39 (0.32–5.99) | 1.21 (0.26–5.58) |
| Antidepressant prescription | 0.82 (0.28–2.40) | 0.83 (0.28–2.44) | 0.78 (0.23–2.63) |

CI: confidence interval; DMTs: disease-modifying therapies; EDSS: Expanded Disability Status Scale; HR: hazard ratio; MS: multiple sclerosis; MSIS-29: MS Impact Scale; N: number of individuals; RRMS: relapsing-remitting MS.

$^a$Model 1: adjusted for sex, country of birth, education, age at DMT start, and geographical region of treatment. Time since DMT start was used as the underlying timescale.

Model 2: further adjusted for history of bipolar disorder, anxiety, and other mental and behavioral disorders in addition to the variables adjusted for in Model 1.

Model 3: further adjusted for disease duration, DMT line, EDSS, and MSIS-29 in addition to the variables adjusted for in Model 2.

*\(p = 0.010\); **\(p = 0.018\).
activity or a possible interaction with depressive symptoms perceived by the patient.

In the analysis of specific DMTs we also detected a higher risk of fingolimod discontinuation in patients treated with antidepressants; however, this association must be interpreted with caution given the chance of random findings.

We also noted a higher risk of MS relapses among patients on natalizumab with depression compared with non-depressed patients. While this observation was confounded by MS severity, it may still indicate that this patient group might be more prone to psychogenic relapses. Although psychogenic causes are well-described as a differential diagnosis to MS, this is more rarely investigated in patients with a confirmed MS diagnosis.

There are certain limitations with this study. First, we had access to psychiatric diagnoses from specialized inpatient and outpatient care but not from primary care, with the consequence of not being able to capture the less complicated depression cases usually treated within the primary care. However, the fact that we had access to complete data of filled prescriptions in pharmacies from both specialized and primary healthcare/general practitioners enabled us to assess all pharmacological interventions, even if this then may include also other indications for these drug classes such as anxiety disorders. Second, we were not able to account for resolution of depression and we did not have access to information on non-pharmacological interventions for depression such as psychological therapy. We also did not have access to family history of depression and were, therefore, unable to investigate whether heritability of depression would modify the association of DMT groups with depression. Third, although the access to more precise disease phenotype information from the Swedish MS Registry made it possible to correct for additional disease-related factors that differed between the DMT groups, we did not account for lesion load and relapse activity, hence residual confounding cannot be ruled out. Finally, although our estimate of a protective effect of rituximab on depression was statistically significant, the CIs were relatively wide, and results should be replicated in larger samples. Larger samples would also give the possibility to separately investigate whether the psychiatric vulnerability of patients with preexisting depression prior to DMT start is also modified by DMT initiation.

In sum, using a contemporary nationwide incident cohort of RRMS patients we detected a lower risk of depression or antidepressant use in patients treated with rituximab, compared with patients treated with interferons. Occurrence of depression or antidepressant use did not affect the overall risk of DMT discontinuation or MS relapse among RRMS patients.

### Table 5. Associations of DMTs with the risk of depression or SSRIs use, and of SSRIs use with the risk of DMT discontinuation or MS relapse among RRMS patients (N = 3803).

|                                | Model 1a          | Model 2a          | Model 3a          |
|--------------------------------|-------------------|-------------------|-------------------|
|                                | HR (95% CI)       | HR (95% CI)       | HR (95% CI)       |
| Risk of depression or SSRIs use|                   |                   |                   |
| Interferons                    | Ref.              | Ref.              | Ref.              |
| Dimethyl fumarate              | 0.82 (0.59–1.13)  | 0.81 (0.59–1.12)  | 0.86 (0.61–1.21)  |
| Fingolimod                     | 0.77 (0.51–1.17)  | 0.79 (0.52–1.20)  | 0.77 (0.49–1.22)  |
| Glatiramer acetate             | 1.13 (0.75–1.70)  | 1.14 (0.76–1.71)  | 0.85 (0.54–1.32)  |
| Natalizumab                    | 1.26 (0.96–1.66)  | 1.24 (0.94–1.63)  | 1.04 (0.77–1.42)  |
| Rituximab                      | 0.78 (0.59–1.03)  | 0.76 (0.58–1.01)  | 0.71 (0.51–0.97)  |
| Risk of DMT discontinuation    |                   |                   |                   |
| SSRIs prescription             | 0.99 (0.88–1.10)  | 0.99 (0.88–1.10)  | 1.00 (0.88–1.13)  |
| Risk of MS relapse             |                   |                   |                   |
| SSRIs prescription             | 1.16 (0.77–1.75)  | 1.18 (0.78–1.78)  | 1.16 (0.76–1.78)  |

CI: confidence interval; DMTs: disease-modifying therapies; EDSS: Expanded Disability Status Scale; HR: hazard ratio; MS: multiple sclerosis; MSIS-29: MS Impact Scale; N: number of individuals; RRMS: relapsing-remitting MS; SSRIs: selective serotonin reuptake inhibitors.

*Model 1: adjusted for sex, country of birth, education, age at DMT start, and geographical region of treatment. Time since DMT start was used as the underlying timescale.

*Model 2: further adjusted for history of bipolar disorder, anxiety, and other mental and behavioral disorders in addition to the variables adjusted for in Model 1.

*Model 3: further adjusted for disease duration, DMT line, EDSS, and MSIS-29 in addition to the variables adjusted for in Model 2.
discontinuation or MS relapse. Additional studies will be needed to explore the existence of a possible causal link and whether biological and/or psychological factors contribute to the observed differences, or whether interferons increase the risk of depression.

Declaration of Conflicting Interests
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: F.P. received research grants from Sanofi-Genzyme, Merck KGaA and UCB, and fees for serving as Chair of DMC in clinical trials with Parexel. E.L., T.F., S.E., J.R, and F.F. declare that there is no conflict of interest. Commercial entity relevant for potential conflicts of interest is: Sanofi-Genzyme (teriflunomide/Aubagio and alemtuzumab/Lemtrada).

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Research reported in this study was partially funded through a Patient-Centered Outcomes Research Institute (PCORI) Award (MS-1511-33196). The content and views reported here are solely the responsibility of the authors and do not necessarily represent the views of PCORI, its Board of Governors, or Methodology Committee. Further funding included the Swedish Research Council (Grant Nos 2017-03054, 2019-01088, and 2016-01355), Karolinska Institutet (Strategic Research Area in Epidemiology and Senior Researcher Award to F.F.), and the Swedish Research Council for Health, Working Life, and Welfare (postdoc Grant No: 2020-0115 to E.L.). The funding sources had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.

ORCID iDs
Elisa Longinetti https://orcid.org/0000-0002-4789-7172
Simon Englund https://orcid.org/0000-0002-1042-4400

Supplemental material
Supplemental material for this article is available online.

References
1. Patten SB, Marrie RA and Carta MG. Depression in multiple sclerosis. Int Rev Psychiat 2017; 29: 463–472.
2. Janssens van Doorn PA, de Boer JB, Kalkers NF, et al. Anxiety and depression influence the relation between disability status and quality of life in multiple sclerosis. Mult Scler 2003; 9(4): 397–403.
3. Bronnum-Hansen H, Stenager E, Nylev Stenager E, et al. Suicide among Danes with multiple sclerosis. J Neurol Neurosurg Psychiat 2005; 76(10): 1457–1459.
4. Johansson V, Lundholm C, Hillert J, et al. Multiple sclerosis and psychiatric disorders: Comorbidity and sibling risk in a nationwide Swedish cohort. Mult Scler 2014; 20(14): 1881–1891.
5. Miller AH and Raison CL. The role of inflammation in depression: From evolutionary imperative to modern treatment target. Nat Rev Immunol 2016; 16(1): 22–34.
6. Colasanti A, Guo Q, Giannetti P, et al. Hippocampal neuroinflammation, functional connectivity, and depressive symptoms in multiple sclerosis. Biological Psychiatry 2016; 80: 62–72.
7. Hillert J and Stawiarz L. The Swedish MS registry—clinical support tool and scientific resource. Acta Neurol Scand 2015; 132(199): 11–19.
8. Alping P, Piehl F, Langer-Gould A, et al. Validation of the Swedish multiple sclerosis register: Further improving a resource for pharmacoepidemiologic evaluations. Epidemiology 2019; 30(2): 230–233.
9. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, et al. The Swedish personal identity number: Possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol 2009; 24(11): 659–667.
10. Ludvigsson JF, Almqvist C, Bonamy AK, et al. Registers of the Swedish total population and their use in medical research. Eur J Epidemiol 2016; 31(2): 125–136.
11. Brooke HL, Talback M, Hornblad J, et al. The Swedish cause of death register. Eur J Epidemiol 2017; 32: 765–773.
12. Ludvigsson JF, Andersson E, Ekborn A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health 2011; 11: 450.
13. Wettermark B, Hammar N, Fored CM, et al. The new Swedish prescribed drug register—Opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007; 16(7): 726–735.
14. Burkill S, Montgomery S, Kockum I, et al. The association between multiple sclerosis and pain medications. Pain 2019; 160: 424–432.
15. Ludvigsson JF, Svedberg P, Olen O, et al. The longitudinal integrated database for health insurance...
and labour market studies (LISA) and its use in medical research. *Eur J Epidemiol* 2019; 34(4): 423–437.

16. White IR and Royston P. Imputing missing covariate values for the Cox model. *Stat Med* 2009; 28: 1982–1998.

17. Hunter SF, Agius M, Miller DM, et al. Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: An analysis from the EPOC (Evaluate Patient OutComes) trial. *J Neurol Sci* 2016; 365: 190–198.

18. Montalban X, Comi G, O’Connor P, et al. Oral fingolimod (FTY720) in relapsing multiple sclerosis: Impact on health-related quality of life in a phase II study. *Mult Scler* 2011; 17(11): 1341–1350.

19. Kunkel A, Fischer M, Faiss J, et al. Impact of natalizumab treatment on fatigue, mood, and aspects of cognition in relapsing-remitting multiple sclerosis. *Front Neurol* 2015; 6: 97.

20. Lang C, Reiss C and Maurer M. Natalizumab may improve cognition and mood in multiple sclerosis. *Eur Neurol* 2012; 67(3): 162–166.

21. Alba Pale L, Leon Caballero J, Samso Buxareu B, et al. Systematic review of depression in patients with multiple sclerosis and its relationship to interferonbeta treatment. *Mult Scler Relat Disord* 2017; 17: 138–143.

22. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. IFNB Multiple sclerosis study group and The University of British Columbia MS/MRI analysis Group. *Neurology* 1995; 45(7): 1277–1285.

23. Schippling S, O’Connor P, Knappertz V, et al. Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial. *J Neurol* 2016; 263(7): 1418–1426.

24. Feinstein A, O’Connor P and Feinstein K. Multiple sclerosis, interferon beta-1b and depression: A prospective investigation. *J Neurol* 2002; 249(7): 815–820.

25. Gasim M, Bernstein CN, Graff LA, et al. Adverse psychiatric effects of disease-modifying therapies in multiple Sclerosis: A systematic review. *Mult Scler Relat Disord* 2018; 26: 124–156.

26. Granqvist M, Borelalm M, Poorgohbad A, et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. *JAMA Neurology* 2018; 75: 320–327.

27. Alping P, Frisell T, Novakova L, et al. Rituximab versus fingolimod after Natalizumab in multiple sclerosis patients. *Ann Neurol* 2016; 79(6): 950–958.

28. Borelalm M, Juto A, Axelsson M, et al. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. *Eur J Neurol* 2019; 26(8): 1060–1067.

29. Robertson MJ, Schacterle RS, Mackin GA, et al. Lymphocyte subset differences in patients with chronic fatigue syndrome, multiple sclerosis and major depression. *Clin Exp Immunol* 2005; 141(2): 326–332.

30. Minden SL, Feinstein A, Kalb RC, et al. Evidence-based guideline: Assessment and management of psychiatric disorders in individuals with MS: Report of the guideline development subcommittee of the American academy of neurology. *Neurology* 2014; 82: 174–181.

31. Brenner P and Piehl F. Fatigue and depression in multiple sclerosis: Pharmacological and non-pharmacological interventions. *Acta Neurol Scand* 2016; 134(Suppl. 200): 47–54.

32. Tarrants M, Oleen-Burkey M, Castelli-Haley J, et al. The impact of comorbid depression on adherence to therapy for multiple sclerosis. *Mult Scler Int* 2011; 2011: 271321–271310.

33. Moore P, Hirst C, Harding KE, et al. Multiple sclerosis relapses and depression. *J Psychosom Res* 2012; 73(4): 272–276.

34. Neilley LK, Goodin DS, Goodkin DE, et al. Side effect profile of interferon beta-1b in MS: Results of an open label trial. *Neurology* 1996; 46(2): 552–554.

35. Solomon AJ, Bourdette DN, Cross AH, et al. The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study. *Neurology* 2016; 87: 1393–1399.